ReviewGenes2017
Gold Nanoparticle Approach to the Selective Delivery of Gene Silencing in Cancer-The Case for Combined Delivery?
Review in Genes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 104 citations in OpenAlex.
- Gold Nanoparticle-Based Precision Medicine Strategies for Glioblastoma: Current Biomedical Applications and Future Outlook.Molecules (Basel, Switzerland) · 2026Review
- Biotin-mediated drug delivery: does the biotin transporter mediate uptake of biotin conjugates?Journal of enzyme inhibition and medicinal chemistry · 2025Article
- Gold Nanoparticles in Nanomedicine: Unique Properties and Therapeutic Potential.Nanomaterials (Basel, Switzerland) · 2024Review
- Targeted gene therapy for cancer: the impact of microRNA multipotentiality.Medical oncology (Northwood, London, England) · 2024Review
- Zebrafish Insights into Nanomaterial Toxicity: A Focused Exploration on Metallic, Metal Oxide, Semiconductor, and Mixed-Metal Nanoparticles.International journal of molecular sciences · 2024Review
- Recent nanotheranostic approaches in cancer research.Clinical and experimental medicine · 2024Review
- Assessing the gene silencing potential of AuNP-based approaches on conventional 2D cell culture versus 3D tumor spheroid.Frontiers in bioengineering and biotechnology · 2024Article
- Review
- Conjugation of microbial-derived gold nanoparticles to different types of nucleic acids: evaluation of transfection efficiency.Scientific reports · 2023Article
- Controlled and Targeted Drug Delivery Using Smart Nanovectors.International journal of drug discovery and pharmacology · 2023Article
- Interventional nanotheranostics in hepatocellular carcinoma.Nanotheranostics · 2023Review
- Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.Cancer communications (London, England) · 2022Review
- Significance of Capping Agents of Colloidal Nanoparticles from the Perspective of Drug and Gene Delivery, Bioimaging, and Biosensing: An Insight.International journal of molecular sciences · 2022Review
- Nanotechnology in drug and gene delivery.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Review
- Nanomedicine for the Delivery of RNA in Cancer.Cancers · 2022Review
- The Nanosystems Involved in Treating Lung Cancer.Life (Basel, Switzerland) · 2021Review
- Recent Advances in Stimulus-Responsive Nanocarriers for Gene Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Disulfide Bridging Strategies in Viral and Nonviral Platforms for Nucleic Acid Delivery.Biochemistry · 2021Review
- Delivery technologies for in utero gene therapy.Advanced drug delivery reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy arises as a great promise for cancer therapeutics due to its potential to silence genes involved in tumor development. In fact, there are some pivotal gene drivers that suffer critical alterations leading to cell transformation and ultimately to tumor growth. In this vein, gene silencing has been proposed as an active tool to selectively silence these molecular triggers of cancer, thus improving treatment. However, naked nucleic acid (DNA/RNA) sequences are reported to have a short lifetime in the body, promptly degraded by circulating enzymes, which in turn speed up elimination and decrease the therapeutic potential of these drugs. The use of nanoparticles for the effective delivery of these silencers to the specific target locations has allowed researchers to overcome this issue. Particularly, gold nanoparticles (AuNPs) have been used as attractive vehicles for the target-specific delivery of gene-silencing moieties, alone or in combination with other drugs. We shall discuss current trends in AuNP-based delivery of gene-silencing tools, considering the promising road ahead without overlooking existing concerns for their translation to clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.